论文部分内容阅读
目的:评价塞来昔布联合XELOX方案治疗晚期胃癌的临床疗效及安全性。方法:选取2015年5月至2016年8月河源市人民医院收治的晚期胃癌患者48例作为研究对象,随机分为对照组(XELOX方案)和试验组(XELOX-C,塞来昔布联合XELOX方案)。21 d为1个周期,治疗2个周期后评价近期疗效与不良反应。结果:对照组有效率37.5%,疾病控制率66.7%;试验组有效率54.2%,疾病控制率91.7%,两组比较,差异均无统计学意义(P>0.05)。两组白细胞减少、贫血、血小板减少、恶心、呕吐、腹泻、口腔黏膜炎及外周神经炎等不良反应发生率比较,差异无统计学意义(P>0.05),但试验组手足综合征发生率明显低于对照组(P<0.05)。结论:塞来昔布联合XELOX方案治疗晚期胃癌可以改善患者的手足综合征,耐受性良好。
Objective: To evaluate the clinical efficacy and safety of celecoxib combined with XELOX regimen in the treatment of advanced gastric cancer. Methods: Forty-eight patients with advanced gastric cancer who were treated in Heyuan People’s Hospital from May 2015 to August 2016 were selected and randomly divided into control group (XELOX regimen) and test group (XELOX-C, celecoxib combined with XELOX Program). 21 d for a period of 2 weeks after the treatment evaluation of the recent efficacy and adverse reactions. Results: In the control group, the effective rate was 37.5% and the disease control rate was 66.7%. The effective rate in the experimental group was 54.2% and the disease control rate was 91.7%. There was no significant difference between the two groups (P> 0.05). The incidence of leukopenia, anemia, thrombocytopenia, nausea, vomiting, diarrhea, oral mucositis and peripheral neuritis in the two groups had no significant difference (P> 0.05), but the incidence of hand-foot syndrome was significantly higher in the experimental group Lower than the control group (P <0.05). Conclusion: Celecoxib combined with XELOX regimen in the treatment of advanced gastric cancer can improve the hand-foot syndrome in patients with good tolerance.